logo

Evofem Biosciences Inc. (EVFM)



Trade EVFM now with
  Date
  Headline
8/26/2019 6:02:49 AM Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial Of Amphora
8/5/2019 4:12:10 PM Evofem Biosciences Q2 Loss/share $0.97 Vs. Loss $1.11 Year Ago
5/7/2019 6:08:11 AM Evofem Biosciences Q1 Loss Attributable To Holders $18.1 Mln Or $0.67/Shr Vs Loss Of $69.1 Mln Or $4.62/Shr Last Year
4/23/2019 8:18:49 AM Evofem Announces Completion Of Patient Enrollment In AMPREVENCE Phase 2b Clinical Trial
4/11/2019 10:29:58 AM PDL BioPharma Announces Investment In Evofem ;to Invest Total Of Up To $60 Mln In Private Placement Of Securities
4/11/2019 10:22:35 AM Evofem Biosciences Reaches Financing Agreement For Up To $80 Mln
3/1/2019 6:09:58 AM Evofem Biosciences Q4 Loss Attributable To Holders $15.0 Mln Or $0.58/Shr Vs Loss Of $20.7 Mln Or $10.55/Shr Last Year
12/17/2018 6:06:52 AM Evofem: Phase 3 Clinical Trial Of Amphora For Prevention Of Pregnancy, AMPOWER, Met Its Primary Endpoint
12/17/2018 6:04:54 AM Evofem Biosciences Says Positive Top-Line Results Of Phase 3 Study Evaluating Amphora For Hormone-Free Birth Control
11/7/2018 6:52:27 AM Evofem Biosciences Q3 Net Loss Attributable $18.4 Mln Or $0.71/Shr
10/3/2018 8:07:39 AM Evofem Biosciences To Present Data On Methodology And Current Status Of Two Ongoing Clinical Studies Of Amphora
  
 
>